



## Catalytic asymmetric synthesis of the docetaxel (Taxotere) side chain: organocatalytic highly enantioselective synthesis of esterification-ready $\alpha$ -hydroxy- $\beta$ -amino acids

Pawel Dziejcz, Jan Vesely, Armando Córdoba\*

Department of Organic Chemistry, Arrhenius Laboratory, Stockholm University, SE-106 91 Stockholm, Sweden

### ARTICLE INFO

#### Article history:

Received 3 August 2008

Revised 26 August 2008

Accepted 5 September 2008


Available online 11 September 2008

### ABSTRACT

A highly enantioselective catalytic route to protected  $\beta$ -amino- $\alpha$ -hydroxy acids, such as the side chain of Taxotere, is presented. The organocatalytic asymmetric reactions between unmodified protected  $\alpha$ -oxyaldehydes and *N*-Boc-protected aryl imines give the corresponding compound with up to >19:1 dr and 99–99% ee.

© 2008 Elsevier Ltd. All rights reserved.

The  $\beta$ -amino- $\alpha$ -hydroxy acid moiety is a common structural component in a vast group of naturally occurring as well as pharmaceutically active molecules.<sup>1</sup> In this context, docetaxel (Taxotere), a synthetic derivative of paclitaxel (Taxol), which is one of the most outstanding cancer chemotherapeutic substances, contains a (2*R*,3*S*)-phenylisoserine side chain.<sup>2</sup>




The importance of  $\alpha$ -hydroxy- $\beta$ -amino acid derivatives has inspired chemists to develop a number of methods for their preparation.<sup>1,3</sup> Among them, Shibasaki and co-workers reported a four-

step synthesis of the Taxotere side chain based on a direct zinc organometallic complex-catalyzed Mannich reaction between an *N*-Boc imine and 2-hydroxy-2'-methoxyacetophenone.<sup>4</sup>

Recently, organocatalysis was added to the synthetic repertoire of the direct Mannich reaction.<sup>5–7</sup> For example, we have reported amino acid-catalyzed Mannich reactions between protected  $\alpha$ -oxyaldehydes, *para*-anisidine, and aldehydes (Eq. 1).<sup>8</sup>


The corresponding *N*-*p*-methoxyphenyl (PMP)-protected  $\alpha$ -oxy- $\beta$ -amino aldehydes are excellent precursors for the synthesis of  $\alpha$ -hydroxy- $\beta$ -amino acids. However, removal of the PMP group requires oxidative conditions, can be low yielding, and requires Boc protection as an additional step. Enders recently reported elegant examples of Mannich-type reactions between ketones and Boc imines.<sup>9</sup> List<sup>10</sup> and our group<sup>11</sup> have also reported that aldehydes can be employed as donors in organocatalytic reactions with Boc imines. Moreover, we recently showed that proline catalyzes the highly enantioselective addition of  $\alpha,\beta$ -unsaturated aldehydes to Boc imines.<sup>12</sup> Based on our previous results and retro-synthetic analysis, we envisioned a short route to the important Taxotere side chain via an amino acid-catalyzed direct Mannich-type



\* Corresponding author. Tel.: +46 8 162479; fax: +46 8 154908.

E-mail addresses: [acordova@organ.su.se](mailto:acordova@organ.su.se), [acordova1a@netscape.net](mailto:acordova1a@netscape.net) (A. Córdoba).

reaction between protected  $\alpha$ -oxyaldehydes and *N*-Boc-protected benzaldimine (Eq. 2).




Herein, we report a highly enantioselective synthesis of the esterification-ready side chain of Taxotere (>19:1 dr, 99% ee). The reaction is a direct route to Boc-protected  $\alpha$ -hydroxy- $\beta$ -aminoaldehydes.

In an initial screen, we found that (*S*)-proline **4** and hydroxyproline **5** catalyzed the reaction between phenyl *N*-Boc-imine **1a** (0.25 mmol) and *tert*-butyldimethylsilyl (TBS)-protected  $\alpha$ -oxyaldehyde **2a** (0.27 mmol) with high stereoselectivity to give the cor-

(*S*)-Proline-catalyzed the formation of protected  $\alpha$ -oxy- $\beta$ -amino aldehyde **3a** in 12–36% yield with >19:1 dr (*syn:anti*) and 99–99% ee in DMF, NMP, and CH<sub>3</sub>CN, respectively, at 4 °C (entries 1–3). The optically active aldehyde **3a** was quite stable but was stored at –20 °C. The highest yield was obtained when CH<sub>3</sub>CN was used as the solvent. Performing the catalytic reaction at room temperature increased the yield of **3a** to 48% without affecting the stereoselectivity (entry 6). Inspired by these excellent results, we decided

**Table 1**

Catalyst screen for the enantioselective reactions between **1a** and **2a**<sup>a</sup>



Entry	Catalyst	Time (h)	Solvent	Temperature (°C)	Yield <sup>b</sup> (%)	dr <sup>c</sup>	ee <sup>d</sup> (%)
1	<b>4</b>	48	DMF	4	12	>19:1	99
2	<b>4</b>	48	CH <sub>3</sub> CN	4	36	>19:1	>99
3	<b>4</b>	48	NMP	4	24	>19:1	99
4	<b>4</b>	48	CHCl <sub>3</sub>	4	Trace	n.d.	n.d.
5	<b>4</b>	48	CH <sub>2</sub> Cl <sub>2</sub>	4	Trace	n.d.	n.d.
6	<b>4</b>	16	CH <sub>3</sub> CN	rt	48	>19:1	99
7	<b>5</b>	16	CH <sub>3</sub> CN	rt	6	>19:1	95
8	<b>4</b>	48	Toluene	4	Trace	n.d.	n.d.

<sup>a</sup> Experimental conditions: A mixture of **1a** (0.25 mmol), aldehyde **2a** (0.50 mmol), and catalyst (20 mol %) in 1.0 mL of solvent was stirred under the conditions displayed in the table.


<sup>b</sup> Isolated yield of pure compound **3a**.

<sup>c</sup> Determined by <sup>1</sup>H NMR of the crude reaction mixture.

<sup>d</sup> Determined by chiral-phase HPLC analysis. n.d. = not determined. TBS = *tert*-butyldimethylsilyl.

**Table 2**

Direct organocatalytic asymmetric Mannich reactions between *N*-Boc-protected imines **1** and  $\alpha$ -oxyaldehydes **2**<sup>a</sup>




Entry	Ar	X	Product	Time (h)	Yield <sup>b</sup> (%)	dr <sup>c</sup>	ee <sup>d</sup> (%)
1	Ph	TBS	<i>ent</i> - <b>3a</b>	40	56	>19:1	99
2	Ph	Bn	<i>ent</i> - <b>3b</b>	5	60	>19:1	99
3	4-MeC <sub>6</sub> H <sub>4</sub>	Bn	<i>ent</i> - <b>3c</b>	16	56	3:1	99
4	4-MeOC <sub>6</sub> H <sub>4</sub>	Bn	<i>ent</i> - <b>3d</b>	16	52	9:1	99

<sup>a</sup> Experimental conditions: A mixture of **1a** (0.25 mmol),  $\alpha$ -oxyaldehyde **2** (0.27 mmol), and (*R*)-proline (20 mol %) in 1.0 mL of CH<sub>3</sub>CN was stirred at room temperature.

<sup>b</sup> Isolated yield of pure compound **3**.

<sup>c</sup> *syn/anti* ratio determined by <sup>1</sup>H NMR analysis.

<sup>d</sup> Determined by chiral-phase HPLC analyses. TBS = *tert*-butyldimethylsilyl. Bn = benzyl.




**Scheme 1.** Reagents and conditions: (a) (*R*)-proline (20 mol %), CH<sub>3</sub>CN, rt, 16 h, 60%; (b) NaClO<sub>2</sub>, *iso*-butene, KHPO<sub>4</sub>, *t*-BuOH/H<sub>2</sub>O 2:1, 85%.

to investigate the catalytic asymmetric Mannich reaction between various *N*-Boc-protected imines **1** and different  $\alpha$ -oxaldehydes **2** (Table 2).<sup>14</sup> In order to achieve the same configuration (2*R*,3*S*) as that of the Taxotere side chain, (*R*)-proline was selected as the organocatalyst.


The (*R*)-proline-catalyzed Mannich reactions proceeded with excellent enantioselectivity, and the corresponding  $\alpha$ -oxy- $\beta$ -amino aldehydes *ent*-**3a**–*ent*-**3d** were obtained in good yields with 99% ee. To our delight, the reaction was highly *syn*-selective (>19:1 dr) when imine **1a** was used as the acceptor (entries 1 and 2). In fact, this is the key transformation for the synthesis of the Taxotere side chain (Eq. 2). For example, (*R*)-proline-catalyzed the asymmetric reaction between imine **1a** and benzyl-protected  $\alpha$ -oxaldehyde **2b** with high diastereo- and enantioselectivity to give the corresponding orthogonally protected  $\alpha$ -oxy- $\beta$ -amino aldehyde *ent*-**3b**<sup>14</sup> in 60% yield with >19:1 dr and 99% ee (entry 2). Moreover, the reactions were readily scaled up. Next, the  $\alpha$ -oxy- $\beta$ -amino aldehyde *ent*-**3b** was oxidized to the corresponding (2*R*,3*S*)-phenylisoserine (Taxotere) side chain **4b**<sup>3g</sup> in high yield (Scheme 1).<sup>15</sup> This reaction can also be performed as a one-pot operation.

Notably, the benzyl-protected  $\beta$ -amino- $\alpha$ -hydroxy acid **4b** is esterification-ready for reaction with 10-deacetylbaaccatin III, an abundant natural product obtained from the yew tree, which after deprotection gives Taxotere (Eq. 3).<sup>3g</sup>



On the basis of the absolute configuration, we propose transition-state model **I** to account for the diastereo- and enantioselectivity of the (*R*)-proline-catalyzed formation of  $\alpha$ -oxy- $\beta$ -amino aldehydes **3** (Fig. 1). Hence, the (*R*)-proline forms an enamine with the aldehyde, which is attacked by the *N*-Boc-protected imine from its *Re*-face providing (2*R*,3*S*)- $\beta$ -amino- $\alpha$ -hydroxy acid derivatives. This is in accordance with the opposite established transition states of previously reported (*S*)-proline-catalyzed Mannich reactions<sup>5,6</sup> with  $\alpha$ -oxaldehydes.<sup>8</sup>

In summary, we have reported a simple, highly enantioselective, organocatalytic asymmetric Mannich-type reaction with  $\alpha$ -oxaldehydes as nucleophiles and Boc-protected imines as acceptors. The corresponding orthogonally protected  $\alpha$ -oxy- $\beta$ -aminoaldehydes were formed in good yields with 99% ee. The importance of this transformation as an entry to the synthesis of  $\alpha$ -hydroxy- $\beta$ -amino acids was further exemplified by the highly stereoselective (>19:1 dr, 99% ee) synthesis of the esterification-ready Taxotere side chain. Further elaboration of this novel



**Figure 1.** Transition-state model evoked to account for the enantioselectivity of the (*R*)-proline-catalyzed reactions.

transformation in total synthesis as well as mechanistic studies is ongoing in our laboratory.

## Acknowledgments

We gratefully acknowledge the Swedish National Research Council and Carl-Trygger Foundation for financial support.

## References and notes

- (a) Juaristi, E.; Quintana, D.; Escalante, J. *Aldrichim. Acta* **1994**, *27*, 3; (b) Cardillo, G.; Tomasi, C. *Chem. Soc. Rev.* **1996**, *29*, 117; (c) Bergmeier, S. C. *Tetrahedron* **2000**, *56*, 2561.
- For selected reviews on these compounds see: (a) Nicolaou, K. C.; Dai, W.-M.; Guy, R. K. *Angew. Chem., Int. Ed. Engl.* **1994**, *33*, 15; (b) Blechert, S.; Guénard, D. In *Brossi, A., Ed.; The Alkaloids, Chemistry and Pharmacology*; Springer: Berlin, 1990; Vol. 39, p 195; (c) Potier, P.; Guénard, D.; Guéritte-Voegelein, F. *Acc. Chem. Res.* **1993**, *26*, 160.
- For selected examples, see: (a) Rubin, A. E.; Sharpless, K. B. *Angew. Chem., Int. Ed.* **1997**, *36*, 2637; (b) Upadhyay, T. T.; Sufalai, A. *Tetrahedron: Asymmetry* **1997**, *8*, 3685; (c) Hanessian, S.; Sancéau, J.-Y. *Can. J. Chem.* **1996**, *74*, 621; (d) Gennari, C.; Carcano, M.; Dongi, M.; Mongelli, N.; Vanotti, E.; Vulpetti, A. *J. Org. Chem.* **1997**, *62*, 4746; (e) Gou, D.-M.; Liu, Y.-C.; Chen, C.-S. *J. Org. Chem.* **1993**, *58*, 1287; (f) Ojima, I.; Habus, I.; Zhao, M.; Georg, G. I.; Jayasinghe, L. R. *J. Org. Chem.* **1991**, *56*, 1681; (g) Kanazawa, A. M.; Denis, J.-N.; Greene, A. E. *J. Org. Chem.* **1994**, *59*, 1238; (h) Denis, J.-N.; Correa, A.; Greene, A. E. *J. Org. Chem.* **1990**, *55*, 1957; (i) Montiel-Smith, S.; Cervantes-Mejía, V.; Dubois, J.; Guénard, D.; Guéritte; Sandoval-Ramírez, J. *Eur. J. Org. Chem.* **2002**, 2260; (j) Kudyaba, I.; Raczkó, J.; Jurczak, J. *J. Org. Chem.* **2004**, *69*, 2844. and references cited therein.
- Matsunaga, S.; Yshida, T.; Morimoto, H.; Kumagai, N.; Shibasaki, M. *J. Am. Chem. Soc.* **2004**, *126*, 8777.
- For reviews see: (a) Córdova, A. *Acc. Chem. Res.* **2004**, *37*, 102; (b) Rios, R.; Córdova, A. *Amino Group Chemistry*. In Ricci, A., Ed.; Wiley-VCH: Weinheim, 2008, Chapter 5, p 185; (c) Ting, A.; Schaus, S. E. *Eur. J. Org. Chem.* **2007**, 5797.
- For selected examples of the use of amino acids as catalysts see: (a) List, B. *J. Am. Chem. Soc.* **2000**, *122*, 9336; (b) Córdova, A.; Watanabe, S.-i.; Tanaka, F.; Notz, W.; Barbas, C. F., III. *J. Am. Chem. Soc.* **2002**, *124*, 1866; (c) Münch, A.; Wendt, B.; Christmann, M. *Synlett* **2004**, 2751; (d) Zhuang, W.; Saaby, S.; Jørgensen, K. A. *Angew. Chem., Int. Ed.* **2004**, *43*, 4476; (e) Fustero, S.; Jimenez, D.; Sanz-Cervera, J. F.; Sanchez-Rosello, M.; Esteban, E.; Simon-Fuentes, A. *Org. Lett.* **2005**, *7*, 3433; (f) Córdova, A.; Barbas, C. F., III. *Tetrahedron Lett.* **2002**, *43*, 7749; (g) Westermann, B.; Neuhaus, C. *Angew. Chem., Int. Ed.* **2005**, *44*, 4077; (h) Ibrahim, I.; Córdova, A. *Tetrahedron Lett.* **2005**, *46*, 3363; (i) Enders, D.; Grondal, C.; Vrettou, M.; Raabe, G. *Angew. Chem., Int. Ed.* **2005**, *44*, 4079; (j) Cobb, A. J. A.;

- Shaw, D. M.; Ley, S. V. *Synlett* **2004**, 558; (k) Cobb, A. J. A.; Shaw, D. M.; Longbottom, D. A.; Gold, J. B.; Ley, S. V. *Org. Biomol. Chem.* **2005**, *3*, 84; (l) Ibrahim, I.; Córdova, A. *Chem. Commun.* **2006**, 1760; (m) Ibrahim, I.; Casas, J.; Córdova, A. *Angew. Chem., Int. Ed.* **2004**, *43*, 6528; (n) Ibrahim, I.; Zou, W.; Casas, J.; Sundén, H.; Córdova, A. *Tetrahedron* **2006**, *62*, 357; (q) Rodriguez, B.; Bolm, C. *J. Org. Chem.* **2006**, *71*, 2888; (r) Ibrahim, I.; Zou, W.; Engqvist, M.; Xu, Y. *Chem. Eur. J.* **2005**, *11*, 7024; (s) Córdova, A. *Synlett* **2003**, 1651; (t) Córdova, A. *Chem. Eur. J.* **2004**, *10*, 1987; (u) Hayashi, Y.; Tsuboi, W.; Ashimine, I.; Urushima, T.; Shoji, M.; Sakai, K. *Angew. Chem., Int. Ed.* **2003**, *42*, 3677; (v) Hayashi, Y.; Urushima, T.; Shoji, M.; Uchimary, T.; Shiina, I. *Adv. Synth. Catal.* **2005**, *347*, 1595.
7. For the use of organic catalysts see: (a) Akiyama, T.; Itoh, J.; Yokota, K.; Fuchibe, K. *Angew. Chem., Int. Ed.* **2004**, *43*, 1566; (b) Uraguchi, D.; Terada, M. *J. Am. Chem. Soc.* **2004**, *126*, 5356; (c) Lou, S.; Taoka, B. M.; Ting, A.; Schaus, S. *J. Am. Chem. Soc.* **2005**, *127*, 11256; (d) Wenzel, E. N.; Jacobsen, E. N. *J. Am. Chem. Soc.* **2002**, *124*, 12964.
8. (a) Ibrahim, I.; Córdova, A. *Tetrahedron Lett.* **2005**, *46*, 2839; (b) Liao, W.-W.; Ibrahim, I.; Córdova, A. *Chem. Commun.* **2006**, 674.
9. (a) Enders, D.; Grondal, C.; Vrettou, M. *Synthesis* **2006**, 2155.
10. (a) Yang, J. W.; Stadler, M.; List, B. *Angew. Chem., Int. Ed.* **2007**, *46*, 609; (b) Yang, J. W.; Chandler, C.; Stadler, M.; Kampen, D.; List, B. *Nature* **2008**, 452, 453.
11. Vesely, J.; Rios, R.; Ibrahim, R.; Córdova, A. *Tetrahedron Lett.* **2007**, *48*, 421.
12. Vesely, J.; Dziedzic, P.; Córdova, A. *Tetrahedron Lett.* **2007**, *48*, 6900.
13. *Typical experimental procedure:* To a stirred solution of imine **1a** (1.0 equiv, 0.25 mmol) and aldehyde **2a** (1.1 equiv, 0.27 mmol) in solvent (1.0 mL) at 4 °C was added (*S*)-proline (20 mol%), and the resulting reaction mixture was stirred vigorously for the reported time. Next, the reaction mixture was directly loaded onto a silica-gel column and immediate chromatography (pentane/EtOAc-mixtures or toluene/EtOAc-mixtures) furnished the corresponding aldehyde **3a**: colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.70 (br s, 1H), 7.36–7.24 (m, 5H), 5.43 (d, *J* = 8.0 Hz, 1H), 5.21 (d, *J* = 8.0 Hz, 1H), 4.22 (br s, 1H), 1.41 (s, 9H), 0.78 (s, 9H), –0.14 (s, 3H), –0.34 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 201.7, 155.2, 139.5, 128.7, 127.8, 126.6, 81.7, 80.3, 55.6, 28.5, 25.8, –5.1, –5.5; HRMS (ESI): calcd for [M+Na] (C<sub>20</sub>H<sub>33</sub>NO<sub>4</sub>SiNa) requires *m/z* 402.2071, found 402.2074. The enantiomeric excess was determined by HPLC with an AD column *n*-hexane/*i*-PrOH = 98:2, λ = 220 nm, 0.5 mL/min; major enantiomer *t*<sub>R</sub> = 16.6 min, minor enantiomer = 24.1 min; [α]<sub>D</sub><sup>25</sup> –10.5 (c 1.0, CHCl<sub>3</sub>).
14. *Typical experimental procedure:* To a stirred solution of imine **1a** (1.0 equiv, 0.25 mmol) and aldehyde **2b** (1.1 equiv, 0.27 mmol) in CH<sub>3</sub>CN (1.0 mL) at room temperature was added (*R*)-proline (20 mol%). The reaction mixture was stirred vigorously for the reported time. Next, the reaction mixture was directly loaded on a silica-gel column, and immediate chromatography (pentane/EtOAc-mixtures or toluene/EtOAc-mixtures) furnished the corresponding aldehyde. *ent-3b*: colorless oil. <sup>1</sup>H NMR (400 MHz): δ 9.73–9.72 (m, 1H), 7.37–7.23 (m, 8H), 7.10–7.06 (m, 2H), 5.52 (br s, 1H), 5.24 (br s, 1H), 4.60 (d, *J* = 11.6 Hz, 1H), 4.39 (d, *J* = 11.6 Hz, 1H), 4.04 (br s, 1H), 1.40 (s, 9H); <sup>13</sup>C NMR (100 MHz): 201.2, 155.2, 139.4, 136.7, 128.8, 128.7, 128.4, 128.3, 127.9, 126.8, 86.0, 80.3, 73.6, 54.3, 28.5; HRMS (ESI): calcd for [M+Na] (C<sub>21</sub>H<sub>25</sub>NO<sub>4</sub>Na) requires *m/z* 378.1676, found 378.1671. The enantiomeric excess was determined by HPLC with an AD column (*n*-hexane/*i*-PrOH = 90:10, λ = 220 nm), 0.5 mL/min; major enantiomer *t*<sub>R</sub> = 15.9 min, minor enantiomer = 28.2 min; [α]<sub>D</sub><sup>25</sup> +29.0 (c 1.0, CHCl<sub>3</sub>).
15. *Preparation of acid 4b:* To a solution of *ent-3b* (0.1 mmol) in chloroform (1 mL), isobutene (0.1 mL), *tert*-butanol (0.4 mL), H<sub>2</sub>O (0.2 mL), KH<sub>2</sub>PO<sub>4</sub> (54.4 mg, 4.0 mmol), and NaClO<sub>2</sub> (36 mg, 4.0 mmol) were added sequentially at room temperature. After 16 h, the crude product was purified by column chromatography (pentane/EtOAc-mixtures) to afford 32 mg (85%) of the desired acid **4b**; colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.37–7.19 (m, 8H), 7.04–7.00 (m, 2H), 5.80 (d, *J* = 8 Hz, 1H), 5.30 (d, *J* = 8.8 Hz, 1H), 4.70 (d, *J* = 10 Hz, 1H), 4.32 (d, *J* = 10 Hz, 1H), 4.20 (br s, 1H), 1.42 (s, 9H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 173.4, 155.9, 139.5, 136.6, 128.8, 128.6, 128.2, 128.0, 127.8, 126.9, 80.6, 80.1, 73.2, 56.0, 28.5; HRMS (ESI): calcd for [M+Na] (C<sub>21</sub>H<sub>25</sub>NO<sub>5</sub>Na) requires *m/z* 394.1625, found 394.1635. [α]<sub>D</sub><sup>25</sup> +19.0 (c 1.0, CHCl<sub>3</sub>).